


## SoftWave's Patented Low-Intensity Shock Wave Technology Accelerates Healing

By John Warlick, Softwave CEO

Extra Corporeal Shock Wave Therapy (ESWT) has been widely used to treat a wide range of conditions, including complex and chronic non-healing soft tissue wounds with different etiologies, such as DFUs, peripheral arterial diseases, venous leg ulcers, and pressure ulcers.

ESWT is an adjunctive therapy that can be combined with standard wound care therapies.

ESWT is an evidence-based, non-invasive, convenient



Patented parabolic reflector applicator spreads energy to a large area of both superficial and deep tissue (7cmx12cm)

SoftWave treatment has a reimbursement pathway with CPT Codes 0512T and 0513T.

This ESWT device is FDA Cleared for activation of connective tissue, treatment of chronic DFUs, treatment of acute second-degree burns, pain reduction and improved blood supply.

ESWT has been demonstrated to positively impact the four stages of wound healing:

- **Inflammation:** Low-energy shock waves can lower the pro-inflammatory response, induce the anti-inflammatory profile in macrophages, and alter the expression of cytokines and chemokines. Shock waves also reduce leukocyte and macrophage infiltration in isograft tissue and decrease the corresponding macrophage-derived inflammatory protein response.

treatment for chronic wounds, including DFUs. One study found that using ESWT to treat chronic wounds resulted in nearly three-fourths (74.03%) of wounds closing and not reappearing in the same location.


Moreover, a meta-analysis that looked at five randomized studies implementing ESWT across multiple types of wounds, including burns and DFUs, found a 20% absolute efficacy advantage for ESWT relative to control treatments and achievement of 50% of the performance goals outlined for ESWT effectiveness.

SoftWave Tissue Regeneration Technologies' DermaGold100® is an advanced patented electrohydraulic technology that produces unfocused, low-intensity parallel shock waves over a broad area resulting in accelerated healing.

DermaGold 100® is a proven option for patients with chronic wounds not responding to standard of care.



- ✓ Faster healing time vs standard of care
- ✓ Non-invasive
- ✓ Fast treatment time
- ✓ No anesthesia or numbing agents
- ✓ Convenient for patient & provider
- ✓ Reimbursement available



## SoftWave

Tissue Regeneration Technologies

- **Infection:** Shock waves have a bactericidal effect and can reduce the bacterial burden of the wound. They also increase the number of microvessels and improve delivery of antibiotics to an infected wound.

- **Apoptosis and necrosis:** Shock wave treatment can decrease cellular apoptosis and reduce the necrosis of wounds.

- **Remodeling and neovascularization:** Shock wave treatment can accelerate granulation and re-epithelialization and reduce scar formation. It also increases overall blood circulation and stimulates cutaneous and muscular microcirculation.

**SoftWave's DermaGold 100® initiates a more rapid and effective healing phase.** It is thought to work by:

- Increasing the blood flow to the wounded area
- Stimulating the neovascularization and growth factors

- Modulating the inflammatory process
- Stimulating osteoclasts and fibroblasts to rebuild injured tissue
- Facilitating resorption of calcification in tendons and ligaments
- Stimulating the migration of resident stem cells

SoftWave's DermaGold 100® is a proven option for patients with chronic wounds not responding to standard of care. It is convenient for both patient and provider. SoftWave treatment has a reimbursement pathway with CPT Codes 0512T and 0513T. *For more information, email [sales@softwavetrt.com](mailto:sales@softwavetrt.com) or [click here](#).*



**62 yr old DFU patient after 4 SoftWave sessions**